A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase 1 Study of the Safety and Tolerability of Intravenously Administered REGN668 in Healthy Volunteers

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase 1 Study of the Safety and Tolerability of Intravenously Administered REGN668 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2013

At a glance

  • Drugs Dupilumab (Primary) ; Dupilumab (Primary)
  • Indications Asthma; Atopic dermatitis
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 26 Feb 2013 Results presented at the 69th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 16 Aug 2010 Actual patient number is 48 according to ClinicalTrials.gov.
    • 16 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top